Kejiyao Pharmaceutical - B(02171.HK) Included in the Southbound Hong Kong Stock Connect Securities List

NightAirdropper · 2026-03-09T02:53:10+00:00

Kejiyao Pharmaceuticals-B (02171.HK) announced that its shares have been included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect Southbound trading eligible stock list, effective from March 9, 2026. This reflects market recognition of the company's CAR-T business and is expected to enhance share liquidity and market attention, driving the development of the capital market.

NightAirdropper

2026-03-09 02:53:10

Abstract generation in progress

Gelonghui, March 9 — Kexi Pharmaceutical-B (02171.HK) announced that, according to the “Notice on the Adjustment of Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect Stocks” issued on March 6, 2026, and the “Announcement on the Adjustment of the List of Stocks under Shenzhen-Hong Kong Stock Connect” also issued on March 6, 2026, the company’s shares issued and listed on the Hong Kong Stock Exchange are now included in the list of eligible stocks for Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Southbound trading (collectively referred to as “Stock Connect”). This adjustment takes effect from March 9, 2026.

This inclusion reflects the market’s recognition of the company’s core CAR-T business development potential, operational compliance, and share liquidity, aligning with the company’s long-term strategic development and the fundamental interests of all shareholders. After being included in Stock Connect, qualified mainland Chinese investors can directly buy and sell the company’s shares listed on the Hong Kong Stock Exchange through the Shanghai and Shenzhen Stock Connect trading systems. This move is expected to provide mainland investors with a more convenient investment channel, significantly increase market attention and liquidity, and inject strong momentum into the company’s capital market development.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes